See more : Yuanda China Holdings Limited (2789.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Todos Medical Ltd. (TOMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Todos Medical Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- PT Tira Austenite Tbk (TIRA.JK) Income Statement Analysis – Financial Results
- Home Plate Acquisition Corporation (HPLTW) Income Statement Analysis – Financial Results
- Element Nutritional Sciences Inc. (ELNSF) Income Statement Analysis – Financial Results
- Info Edge (India) Limited (NAUKRI.BO) Income Statement Analysis – Financial Results
- Alkuri Global Acquisition Corp. (KURI) Income Statement Analysis – Financial Results
Todos Medical Ltd. (TOMDF)
About Todos Medical Ltd.
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.70M | 12.23M | 5.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.39M | 7.85M | 3.82M | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.31M | 4.38M | 1.39M | -29.64K | -25.65K | -24.08K | -20.70K | -11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 56.01% | 35.84% | 26.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 620.00K | 824.00K | 9.86M | 755.70K | 459.18K | 720.53K | 317.91K | 374.02K | 336.47K | 377.31K | 312.17 |
| General & Administrative | 0.00 | 9.36M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Selling & Marketing | 0.00 | 3.48M | -3.06M | -667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.85M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Other Expenses | 0.00 | 0.00 | -53.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.06M | 13.67M | 15.65M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Cost & Expenses | 17.44M | 21.52M | 19.47M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Interest Income | 0.00 | 28.61K | 13.37K | 959.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Interest Expense | 14.85M | 28.61M | 3.83M | 958.74K | 75.43K | 12.44K | 78.78K | 0.00 | 0.00 | ||
| Depreciation & Amortization | 750.00K | 763.00K | 96.00K | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 434.00 | 275.00 | 0.28 |
| EBITDA | -9.39M | -9.72M | -14.17M | -7.78M | -1.35M | -1.31M | -708.19K | -819.08K | -400.41K | -339.26K | -244.22 |
| EBITDA Ratio | -122.08% | -59.33% | -465.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.75M | -9.29M | -14.26M | -3.52M | -1.38M | -1.34M | -728.89K | -830.98K | -400.85K | -339.53K | -244.49 |
| Operating Income Ratio | -126.68% | -75.93% | -273.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.23M | -34.03M | -15.51M | -8.30M | 921.34K | -1.34M | 75.43K | 12.44K | 78.78K | -42.29K | -11.63 |
| Income Before Tax | -24.98M | -43.31M | -29.77M | -11.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -381.82K | -256.12 |
| Income Before Tax Ratio | -324.64% | -354.16% | -571.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | 31.61M | 2.63M | -2.01M | 871.34K | -2.68M | 0.00 | 0.00 | 0.00 | -38.18K | -25.37 |
| Net Income | -24.99M | -74.92M | -32.40M | -9.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -343.64K | -230.75 |
| Net Income Ratio | -324.81% | -612.60% | -622.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
| Weighted Avg Shares Out (Dil) | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022
Todos Medical clinical laboratory Provista Diagnostics submits emergency use application for its PCR monkeypox test
Todos Medical pursuing New York Stock Exchange listing, it says in a wide-ranging update into new business developments
Todos Medical touts successful pilot launch of suite of PCR testing services by its lab Provista Diagnostics
Todos Medical set to be granted two patents for its TBIA pan-cancer blood diagnostics platform
Todos Medical announces receipt of notice of allowance for its 3CL protease biomarker diagnostics TolloTest
Todos Medical strikes $50M contact with Nerd Hemp to distribute Tollovid and CBD products in AI retail machines across the US
Todos Medical announces NFL Hall of Famer Michael Irvin as Tollovid Sports Ambassador for #TolloUp campaign
Todos Medical initiates validation plan for PCR-based polio testing at its Provista Diagnostics laboratory
Todos Medical partner NLC Pharma assigns IP for Tollovir, Tollovid, and TolloTest to joint venture 3CL Pharma
Source: https://incomestatements.info
Category: Stock Reports